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Abstract
The effects of serotonin (5-HT) on tumor growth are inconsistent. We investigated whether a decreased level of
5-HT affected tumor growth using 5-HT transporter knockout (5-HTT−/−) mice, which showed 5-HT depletion. When
cancer cells were injected subcutaneously into both 5-HTT−/− and 5-HTT+/+ mice, the tumor growth was markedly
attenuated in 5-HTT−/− mice. Serotonin levels in the blood, forebrain, and tumors of 5-HTT−/− mice bearing tumors
were significantly smaller than those of their 5-HTT+/+ littermates. However, 5-HT did not increase cancer cells’ pro-
liferation in vitro. When we applied 5-HTT inhibitors to the wild mice bearing tumors, they did not inhibit tumor
growth. The endothelial nitric oxide synthase (eNOS) expressions in tumors were reduced in 5-HTT−/− mice com-
pared with 5-HTT+/+ mice. Stimulations with 5-HT (1-50 μM) induced eNOS expressions in human umbilical vein
endothelial cell (HUVEC) in a concentration-dependent manner. When we measured activations of multiple signaling
pathways by using a high-throughput phosphospecific antibodies platform, 5-HT stimulated the extracellular signal–
regulated kinase 1/2 (ERK1/2) in HUVEC. Moreover, we found that the physiological level of 5-HT induced phosphory-
lation of both ERK1/2 and eNOS in HUVEC. Human umbilical vein endothelial cell expressed both 5-HT2B and 5-HT2C
receptors. SB204741, a specific 5-HT2B receptor inhibitor, blocked 5-HT–induced ERK1/2 and eNOS phosphoryla-
tions, whereas RS102221, a specific 5-HT2C receptor inhibitor, did not in HUVEC. SB204741 reduced microvessel
density in tumors and inhibited the proliferation of HUVEC in vitro. These results suggest that regulation of 5-HT
and 5-HT receptors, especially the 5-HT2B receptor, may serve as a therapeutic strategy in cancer therapy.
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Introduction
The results of clinical studies have thus far failed to show whether
psychological factors affect cancer development [1]. We previously re-
ported that emotions induced by hyperdopaminergic transmission,
such as haloperidol-sensitive delirium, attenuate tumor growth [2,3].
The neurotransmitter serotonin (5-hydoxytryptamine [5-HT]) is caus-
ally involved in multiple central nervous facets of mood in regulat-
ing sleep, anxiety, alcoholism, drug abuse, food intake, and sexual
behavior. The effect of 5-HT on tumor growth is still unclear [4–7].
Moreover, it has been reported that exogeneously applied high doses of
5-HTexert a direct mitogenic effect on tumor cells, whereas low doses
of 5-HT reduce tumor growth by decreasing the blood supply to
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the tumors [7], suggesting that the role of 5-HT on tumor growth is
concentration-dependent on 5-HT. Among the subtypes of 5-HT re-
ceptors, which have been identified (5-HT1-7) based on their structural,
functional, and pharmacological characteristics [8], several subtypes
have been found to exist in cancers [9–11]. The 5-HT2 receptor sub-
family consists of three members, i.e., 5-HT2A, 5-HT2B, and 5-HT2C
receptors. The 5-HT2B receptor has been detected in many peripheral
organs in several mammalian species including humans, primarily in
the cardiovascular system, the gut, and the stomach fundus [12–18].
Especially, the blockade of 5-HT2B is known to inhibit colon cancer
and a prostate cancer cell line [11,19].
Nitric oxide (NO) is a major endothelium-derived relaxing factor
[20]. Vasoconstriction is caused by activation of 5-HT1D and 5-HT2A
receptors on vascular smooth muscle cells [21], whereas vasodilatation
has been attributed to activation of 5-HT2B receptors on endothelial
cells, mediating the release of relaxing factors [22,23]. Endothelial ni-
tric oxide synthase (eNOS), which produces NO in endothelial cells,
plays a major role in inhibiting vasoconstriction to 5-HT [24,25]. En-
dothelial nitric oxide synthase is known to be stimulated by 5-HT
[26]. Moreover, eNOS plays a role in the angiogenesis of tumor
growth [27]. The levels of eNOS were found to increase in the car-
cinoma and to promote cancer progression by providing a selective
growth advantage to tumor cells [28].
In peripheral tissues, 5-HT regulates vascular tone, gut mortality,
primary homeostasis, and cell-mediated immune response [29,30].
Enterochromaffin cells produce and secrete far more 5-HT than either
the central or the peripheral serotonergic neurons. The secreted 5-HT
overflows to reach the peripheral blood by platelets [31–34]. Platelets,
which do not synthesize 5-HT, are totally dependent on uptake to ob-
tain 5-HT [30]. In 5-HT transporter (5-HTT) knockout mice, the
level of 5-HT in the peripheral blood is virtually nil [34].
Although the concentration of 5-HT in the plasma has been shown
to vary depending on psychological state, the level of hypertension, poly-
morphism in the 5-HTT-linked promoter region, and use of 5-HT re-
uptake inhibitors (selective serotonin reuptake inhibitors, SSRIs), the
effect of a decreased level of 5-HTT on tumor growth has not been
heretofore studied. Use of SSRI has been reported to reduce the risk
of colorectal cancer in a large case-control study [35]. These studies
suggest the existence of a strong relationship between 5-HT and cancer
growth. Therefore, using 5-HTT−/− mice, we investigated whether a
decreased level of 5-HT affects tumor growth. In the present study,
we found that specific inhibition of the 5-HT2B receptor inhibited im-
planted lung cancer tumors in mice. On the basis of the analysis of a
decreased level of 5-HT on tumor growth, we clarified the molecular
mechanisms of the cancer inhibition by 5-HT2B blockade.
Materials and Methods
Animals
Six- to 9-week-old male mutant mice lacking 5-HTT and litter-
mate wild-type mice were obtained from heterozygous crosses with a
129Sv/C57BL6 mixed genetic background. Details of the generation of
5-HTT−/− mice have been described previously [36]. We generated ho-
mozygous, heterozygous, and wild mice by crossing adult heterozygotes.
DNA extract for tail biopsies were genotyped using polymerase chain re-
action (PCR). Mice were group housed (two to four per cage) with food
and water ad libitum in a room maintained at 22 ± 2°C and 65 ± 5% hu-
midity under a 12-hour light-dark cycle. The animals were killed with an
overdose of urethane (20 g/kg). All animal experiments were performed
according to the Animals (Scientific Procedures) Act 1986 and approved
by the local ethics panel at the Tohoku University School of Medicine.
Cell Culture
Lewis lung carcinoma (LLC), B16F0, and KLN205 cells were pur-
chased from American Type Culture Collection (Manassas, VA).
Lewis lung carcinoma and B16F0 cells were cultured in high-glucose
Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum,
100 U/ml penicillin, and 0.1 mg/ml streptomycin. KLN205 cells were
cultured in minimum essential medium containing 10% fetal calf serum,
1% nonessential amino acids, and 100 μg/ml kanamycin. Human um-
bilical vein endothelial cells (HUVECs) were purchased from Kurabo
(Osaka, Japan) and cultured in EC growth medium (Kurabo).
In Vivo Tumor Models
LLCs or B16F0 cells were injected (1 × 106 cells per animal) sub-
cutaneously (s.c.) into the flank of male 6- to 9-week-old wild-type and
5-HTT−/−mice on day 0. KLN205 cells were injected (5 × 105 cells per
animal) s.c. into the flank of male 6- to 9-week-old BDF1 mice on day 0.
In solid-tumor growth experiments, paroxetine (20 mg/kg), fluvoxamine
(20 mg/kg), SB204741 (N -(1-methyl-5-indolyl)-N -(3-methyl-5-
isothiazolyl) urea), or RS102221 (8-[5-(5-amino 2,4-dimethoxyphenyl)
5-oxopentyl]-1,3,8-triazaspiro[4,5] decane-2,4-dione) (Tocris Cookson,
Inc, Ellisville, MO) was injected intraperitoneally (i.p.) every 2 days
from day 6. Tumor size was quantified daily as width2 × length ×
0.52. Mice inoculated with LLCs, those inoculated with B16F0 cells,
and those inoculated with KLN205 cells were killed on days 23, 19,
and 33, respectively. Control mice were treated with DMSO or saline.
Cell Proliferation Assays
The cell proliferation assay was performed as previously described
[37]. Briefly, LLCs, KLN205, or HUVEC (5 × 103 cells) were plated
onto 96-well plates and incubated with 0, 1, 10, and 100 μM SB204741
or RS102221. Each cell was cultured for 48 hours, and then the num-
ber of cells was determined by water-soluble tetrazolium assay using a
cell counting kit (Dojindo, Kumamoto, Japan).
Detection of 5-HT Receptor mRNA by Reverse
Transcription–Polymerase Chain Reaction Analysis
Total RNAwas extracted from the cells using RNAzol B reagent (Tel-
Test, Friendswood, TX) following the manufacturer’s instructions.
Reverse transcription–polymerase chain reaction analyses for 5-HT2A,
5-HT2B, and 5-HT2c receptors were performed as previously described
[21,38]. cDNA obtained by oligo-dT primed reverse transcription of
total RNA isolated from HUVEC was subjected to PCR amplification
with receptor-specific primers: 5-HT2A receptor 5′-TCTTTAAGG-
CGGGGAGTTGCT-3′ and 5′-TTTTGCTCATTGCTGATG-
GACTG-3′; 5-HT2B receptor 5′-TGCCATTCCAGTCCCTATT-3′
and 5′-GTGGATGT- TCTTCGCATAAGT-3′; 5-HT2C receptor
5′-TGCATTCATTCCT- TGTGCAC-3′ and 5′-ATATCTAGG-
TAGTGGCCAGA-3′; and the glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) 5′-GTCTTC- ACCACCATGGAGAA-3′
and 5′-ATCCACAGTCTTCTGGGT- GG-3′. Polymerase chain re-
action products were separated by 1.5% agarose gel electrophoresis
and visualized by ethidium bromide staining.
Protein Analysis
When the diameter of the tumor became 1 cm, tumor tissues were
suspended in a lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mMNaCl,
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0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA) containing pro-
tease inhibitors (20 mg/ml leupeptin, 1 mg/ml pepstatin A, and 1 mM
PMSF) and then sonicated on ice. After centrifugation at 16,000g for
15 minutes, the supernatant was eluted in an SDS sample buffer
(60 mM Tris-HCl, pH 6.7, 3% SDS, 2% 2-mercaptoethanol, and
5% glycerol) for 5 minutes. Next, 2 × 105 HUVECs were seeded
in 10-cm dishes, cultured for 2 days, serum-starved (0.1% serum)
for 24 hours, and then treated with various concentrations of 5-HT
(0-50 μM). Cells treated with 5-HTor saline were suspended in a lysis
buffer containing protease inhibitors and then sonicated on ice. Cell
extracts were centrifuged, and the supernatant was boiled and sub-
jected to 10% SDS-PAGE for transfer onto polyvinylidene difluoride
membranes (Millipore, Billerica, MA). Each membrane was blotted
with Abs to eNOS, phospho-eNOS (Ser 1177), extracellular signal–
regulated kinase 1/2 (ERK1/2), and phospho-ERK1/2 (Cell Signaling
Technology, Beverly, MA). Anti–5-HT2B receptor, –5-HT2C receptor,
and –5-HTTwere purchased from Santa Cruz Biotechnology, Santa
Cruz, CA. The membranes were developed with an ECLWestern Blot-
ting Detection System Advance (Amersham Biosciences, Bucks, United
Kingdom) according to the manufacturer’s instructions. Phosphoprotein
detection was performed by using the human phospho-MAPK assay
Array kit (R&D Systems, Minneapolis, MN) according to the manu-
facturer’s instructions. Image analysis was performed with ImageJ 1.37
software (National Institutes of Health, Bethesda, MD).
Immunohistochemistry
When the tumor diameter became 1 cm, under deep pentobarbital
anesthesia (50 mg/kg body weight, i.p.), mice were perfused trans-
cardially with 4% formaldehyde in a 0.1-M phosphate buffer. Tumor
tissues were fixed in 10% formalin, embedded in paraffin, and sec-
tioned. They were blocked with 10% normal goat serum and incu-
bated with polyclonal antihuman factor VIII–related Ag Ab (Dako
Japan, Kyoto, Japan). Subsequently, the sections were incubated with
biotinylated goat antirabbit IgG (Vector Laboratories, Burlingame,
CA), and then treated with the ABC kit (Vector Laboratories), for
the detection of factor VIII–related Ag by 3-amino-9-ethylcarbazole
(Vector Laboratories), and counterstained with hematoxylin.
Fluorescent Immunostaining
Sample preparation was the same as above. Sections (12 μm in thick-
ness) were cut from the frozen tumor with a cryostat (CM1900;
Leica, Heidelberg, Germany) and mounted onto glass slides (Dako,
Carpinteria, CA). After incubation with 10% goat serum (Nichirei,
Tokyo, Japan) for 1 hour at room temperature, the sections were in-
cubated with mice monoclonal anti–factor VIII antibody (1:100) and
rabbit polyclonal anti–phsopho-eNOS antibody (1:500; Cell Signal-
ing Technology) for 36 hours at 4°C. Sections were subsequently in-
cubated with fluorescein isothiocyanate–conjugated antimouse and
Cy3-conjugated antirabbit IgG antibodies (1:100; Chemicon, Temecula,
CA) for 1 hour at room temperature. Sections were then mounted on
coverslips using antifade mounting medium (Vectashield; Vector Labora-
tories) and viewed using a confocal laser microscope (LSM 510; Carl
Zeiss Meditec, Oberkochen, Germany).
Determination of Microvessel Density
Intratumoral microvessel density (MVD) was determined as previ-
ously described [37]. In brief, intratumoral vessels were stained immuno-
histochemically with antihuman factor VIII–related Ag Ab. The
image that contained the highest number of microvessels was chosen
for each section by initial scan at a magnification of ×100, and then
the vessels were counted in the selected image at a magnification of
×200. At least four fields were counted for each section, and the high-
est count was then used. Two independent investigators evaluated the
number of vessels.
Measurement of 5-HT
Serotonin was measured in the forebrain, tumors, and blood of wild
type and 5-HTT−/− mice. These samples were prepared as previously
described [39]. The prepared samples from the forebrain, tumors,
and blood were used for the assay of 5-HT by HPLC with electro-
chemical detection.
Cytokine Enzyme-Linked Immunosorbent Assays
The concentrations of vascular endothelial growth factor (VEGF)
in the plasma, and cell culture supernatants were determined using a
murine VEGF ELISA kit (R&D Systems) according to the manufac-
turer’s recommendation. Lewis lung carcinomas or B16F0 cells were
injected (1 × 106 cells per animal) subcutaneously (s.c.) into the flank
of male 6- to 9-week-old wild-type and 5-HTT−/− mice on day 0.
Tumor size was quantified daily as width2 × length × 0.52. Mice in-
oculated with LLCs were killed on day 23. The inferior vena cava of
the mouse was then punctured, peripheral blood was collected, and
plasma was isolated.
Data Analysis
Statistical analysis of the results was performed using analysis of
variance (ANOVA) with Fisher’s least significant difference test for
multiple comparisons. A value of P < .05 was considered significant.
Results
Decreased Tumor Growth in 5-HTT Knockout Mice
The immunoblot analysis of implanted tumor homogenate by mu-
rine 5-HTTantibody showed the existence of 5-HTT in the 5-HTT+/+
mice but not in the 5-HTT−/− mice (Figure 1A, insert). As shown
in Figure 1, A and B, the tumor growth was markedly attenuated in
5-HTT−/−mice. To test whether this growthmight reflect a direct effect
of 5-HTon LLCs or B16F0 cells, we examined the response of LLCs
or B16F0 cell to 5-HT in vitro. We found that 5-HT did not increase
LLCs or B16F0 cells proliferation in vitro (data not shown). To quan-
tify tumor angiogenesis, we stained tumors with an antibody against
the factor VIII–related antigen, a blood vessel marker (Figure W1)
[40]. There was no difference in tumor MVD estimated by factor
VIII–related antigen staining between 5-HTT−/− and 5-HTT+/+ mice.
Moreover, to examine the level of VEGF in the culture supernatant
fluid, we performed enzyme-linked immunosorbent assay. There were
no differences among LLCs and B16F0 cells with 5-HTor saline treat-
ment (data not shown).
Decreased Level of 5-HT in Tumors of 5-HTT−/− Mice
We reported that 5-HTT−/− mice displayed reduced levels of 5-HT
in the frontal cortex [36]. Next, we focused on 5-HT analyses of the
tumor and peripheral blood. Mice lacking 5-HTT were generated,
and either LLCs or B16F0 cells were injected (1 × 106 cells per animal)
s.c. into the flank of both 5-HTT−/− and 5-HTT+/+ 6-week-old mice
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on day 0. The tumor size was quantified daily, and mice were killed on
day 23. As shown in Figure 1C , in 5-HTT−/− mice bearing LLC tu-
mors, electrochemical detection of 5-HTshowed a level of 5-HT in the
blood below the level of detection. Serotonin levels in the forebrain of
5-HTT−/− mice bearing LLC tumors were significantly lower than
those of their 5-HTT+/+ littermates with LLC tumors. Serotonin levels
of LLC or B16F0 tumors were also significantly lower in 5-HTT−/−
mice than in 5-HTT+/+ mice.
5-HTT Inhibitors Did Not Decrease Tumor Growth
It has been reported that 5-HTT inhibitors inhibit cancer initia-
tion by inhibition of 5-HT reuptake [41]. We thus investigated
whether the 5-HTT inhibitors influence tumor growth. Lewis lung
carcinoma cells were inoculated into the flank of C57BL/6J mice s.c.
on day 0. From day 6 after tumor identification, we i.p. injected
paroxetine, a 5-HTT inhibitor; fluvoxamine, a 5-HTT inhibitor;
or saline every 2 days. Compared with saline treatment, paroxetine
or fluvoxamine treatment did not inhibit tumor growth (Figure 2A).
Moreover, we investigated the influence between 5-HTT inhibitors
and another cancer cell line, KLN205. In the KLN205 tumor growth
model, there were no differences between saline treatment and 5-HTT
inhibitors (Figure 2B). Serotonin levels in the whole blood of mice
treated with paroxetine or fluvoxamine were significantly lower than
those of mice treated with saline (Figure 2C ), but the 5-HT levels in
tumors did not differ among saline-, paroxetine-, and fluvoxamine-
treated mice (Figure 2D). These results suggest that levels of 5-HT in
the tumor but not in the whole blood might influence tumor growth.
Decreased eNOS Expression in 5-HTT−/− Mice
Because eNOS plays a major role in inhibiting contraction of ar-
teries to 5-HT, we next investigated the expression of eNOS in LLC
tumors from 5-HTT−/− mice, which had 5-HT levels in the whole
blood. We found that eNOS protein expression in tumors was lower
in 5-HTT−/− mice than in 5-HTT+/+ mice (Figure 3A). As shown in
Figure 3B, stimulation with 5-HT (1-50 μM) for 24 hours induced
eNOS expression in HUVEC in a concentration-dependent manner.
Next, we investigated whether 5-HT induced signaling pathways in
HUVEC. According to previous reports, 5-HT induced phosphoryla-
tion of MAPK and Akt in various cell types [42]. However, HUVEC
has not been studied yet. We measured the phosphorylation of multiple
signaling pathways by using a high-throughput phosphospecific anti-
bodies platform. Human umbilical vein endothelial cells were treated
with or without 1-μM 5-HT, and cell signaling was assessed. As shown
in Figure 3C , 5-HT stimulation modulated the ERK1/2 in HUVEC.
These results suggest that 5-HT stimulation may induce eNOS expres-
sion through the ERK1/2 phosphorylation in HUVEC.
Stimulation of 5-HT2B Receptor Induced the Phosphorylation
of eNOS through ERK1/2 in HUVEC
Phosphorylation of eNOS produced more bioavailability of the sig-
naling molecule nitric oxide (NO) than eNOS. Endothelial nitric
oxide synthase is phosphorylated in response to various forms of cel-
lular stimulation in endothelial cells [43]. In the present study, we
investigated whether eNOS phosphorylation was induced by 5-HT
in HUVEC in detail. We stimulated HUVEC with various concen-
trations of 5-HT for 10 minutes. phosphorylations of ERK1/2 and
Figure 1. Effects of 5-HT on tumor growth in mice. (A) A total of 1 × 106 LLC cells were implanted into 5-HTT−/− and 5-HTT+/+ mice.
Tumor volumes were calculated from tumor measurements scored on the indicated day. Results are presented as the mean tumor
volume ± SD (n = 6, 7 per group). Insert shows Western blot analysis of 5-HTT protein in tumors of 5-HTT−/− and 5-HTT+/+ mice.
(B) A total of 1 × 106 B16F0 cells were implanted into 5-HTT−/− and 5-HTT+/+ mice. Tumor volumes were calculated from tumor mea-
surements scored on the indicated day. Results are presented as the mean tumor volume ± SD (n= 6 per group). (C) Serotonin in whole
blood, forebrain, and tumors of 5-HTT−/− and 5-HTT+/+ mice on day 23 (LLC) after implantation. Serotonin in tumors of 5-HTT−/− and
5-HTT+/+ mice on day 19 (B16F0) after implantation. Values represent the mean ± SD (n = 6, 7 per group). Statistically significant
(*P < .05, **P < .01) compared with 5-HTT+/+ mice.
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eNOS were concentration-dependent of 5-HT (Figure 4A). As shown
in Figure 4B, 1-μM 5-HT caused transient phosphorylation of both
ERK1/2 and eNOS. Next, we examined the effect of U0126 or PD
98059, which are ERK1/2 inhibitors, on 5-HT–induced ERK1/2
phosphorylation. Human umbilical vein endothelial cells treated with
U0126 or PD 98059 blocked not only ERK1/2 phosphorylation but
also eNOS phosphorylation (Figure 4C ). Moreover, we investigated
what types of 5-HT receptors induced ERK1/2 phosphorylation in
HUVEC. Reverse transcription–polymerase chain reaction and Western
blot analysis revealed that 5-HT2B and 5-HT2C receptors were
expressed in HUVEC (Figure 4, D and E). SB204741, which is a
specific 5-HT2B receptor inhibitor, blocked 5-HT–induced ERK1/2
and eNOS phosphorylation, whereas RS102221, which is a specific
5-HT2C receptor inhibitor, did not (Figure 4F ). These results suggest
that the 5-HT2B receptor plays a pivotal role in HUVEC and that
inhibition of the 5-HT2B receptor may reduce tumor growth.
Figure 2. Paroxetine and fluvoxamine did not decrease tumor growth. (A) Mice were injected s.c. with LLC on day 0 and were treated
with saline (closed squares), paroxetine (circles), or fluvoxamine (open squares) from day 6, every 2fs days. (B) Mice were injected s.c.
with KLN205 on day 0 and were treated with saline (closed squares), paroxetine (circles), or fluvoxamine (open squares) from day 6,
every 2 days. Tumor volumes were calculated from tumor measurement scored on the indicated day. Results are presented as the mean
tumor volume ± SD. (C, D) On day 23 (LLC) or 33 (KLN205) after implantation 5-HT in whole blood and tumors of mice with paroxetine,
fluvoxamine, or saline. *Statistically significant (P < .05) compared with saline-treated mice. The values represent the mean ± SD
(n = 8 per group).
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SB204741 Reduced Tumor Growth
We investigated whether inhibition of the 5-HT2B receptor influ-
enced tumor growth in vivo because the 5-HT2B receptor antagonist
reduced 5-HT–induced ERK1/2 and eNOS phosphorylation.
KLN205 cells were inoculated into the flank of BDF1 mice s.c. on
day 0. From day 6 after tumor identification, we injected SB204741
(20 mg/kg), RS102221 (20 mg/kg), or DMSO, as a control, i.p. every
2 days. Compared with DMSO treatment, SB204741 treatment in-
hibited tumor growth (Figure 5A). Similar results were obtained from
the inoculation of LLCs (Figure 5B). We next examined the direct
effect of SB204741 or RS102221 on the proliferation of HUVEC,
LLCs, and KLN205 cells with various concentrations of these inhibi-
tors. SB204741 reduced the proliferation of HUVEC and KLN205
cells in vitro (Figure W2). These results suggest that SB204741 reduced
tumor growth because SB204741 inhibited the proliferation of the
endothelial cells and KLN205 cells.
SB204741 Treatment Decreased Blood Vessel Density in
Tumor Tissues
Hematoxylin and eosin staining of the tumor tissues revealed a
decrease in vessels in KLN205 and LLC tumor tissues taken from
SB204741-treated mice (Figure 5, C and D). To confirm the vessels,
we stained paraffin sections immunohistochemically using an anti-
body against factor VIII–related Ag. Compared with DMSO-treated
mice, we found fewer tumor vessels in SB204741-treated mice. The
localization of phospho-eNOS in the LLC tumor tissues was deter-
mined by fluorescent immunostaining (Figure 6B). Immunostainning
of phospho-eNOS was observed in the endothelial cells and com-
pletely overlapped that of factor VIII–related Ag. The differences in
MVD between control and SB204741 mice were statistically signifi-
cant (Figure 6A).
Discussion
This is the first study to extensively examine the effect of depletion
of 5-HT on tumor growth in vivo. Conflicting results have been re-
ported on the effect of exogeneously applied 5-HT on tumor growth
[6]. In this study, we therefore investigated the effect of a low level
of 5-HT, i.e., which is lower than the physiological level of 5-HT, on
tumor growth. Using 5-HTT–deficient mice, we found that 5-HT
levels in the tumor played a crucial role in tumor growth, suggesting
that physiological levels of 5-HT in the tumor are needed for tumor
growth. In addition, we found that SB204741, which is a 5-HT2B
receptor inhibitor, suppressed the phosphorylation of ERK1/2 and
eNOS in HUVEC. Moreover, we found that SB204741 reduced
tumor growth by suppressing angiogenesis.
Although the inoculated cancer cells were not knocked out of
5-HTT, there was no 5-HTT protein in tumors implanted in 5-HTT
mice, suggesting that the 5-HTT protein is completely absent in our
5-HT depletion models. Other methods to deplete 5-HT, such as delet-
ing enzymes involved in 5-HT synthesis (tryptophan hydroxylases),
Figure 3. Association between 5-HT and eNOS. (A) LLC tumors from 5-HTT−/− mice decreased eNOS. (B) Effects of 5-HT on 5-HT–
induced eNOS in cultured HUVEC. Serotonin or saline was added to cultured HUVEC for 24 hours. Cells were collected for extraction
and immunoblot analysis with antibodies to eNOS and β-actin. (C) Effects of serotonin on 5-HT–induced signaling pathways in cultured
HUVEC. Saline or 5-HT, 1 μM, was added to cultured HUVEC for 10 minutes. Phosphorylation of intracellular signaling molecules was
assessed by using the human Phospho-MAPK Array kit. The columns present the results of the densitometric analysis of the dot images
corresponding to the phosphorylation status of individual protein. *Statistical significance was determined by 2-tailed-Student’s t test.
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may not work as long as LLC and B16F0 have the enzyme. If we knock
out the enzyme in LLC and B16F0, we cannot exclude the possibility
that the absence of the enzyme affects the proliferation and synthesis of
LLCs and B16F0 cells.
Selective serotonin reuptake inhibitors are the most commonly pre-
scribed drugs for treating depression. Therefore, the effects of SSRIs on
cancer have been studied. Although it has been reported that SSRIs
have cytotoxic activity against colorectal cancer [7,41,44], our results
showed that paroxetine and fluvoxamine did not reduce tumor growth
in vivo. Selective serotonin reuptake inhibitors are known to de-
crease whole-blood 5-HT concentrations in patients [45]. In this study,
although paroxetine and fluvoxamine decreased the whole blood
5-HT concentration, it did not influence the 5-HT level in the tumor.
These results suggest that the 5-HT levels in the tumor could be
important, whereas SSRIs might have a different influence in each
cancer type [44].
Figure 4. Stimulation of 5-HT2B receptor induced the phosphorylation of eNOS through ERK1/2 in HUVEC. (A) Effect of doses of 5-HT
incubated for 10 minutes on phosphorylation of ERK1/2 and eNOS in HUVEC. (B) Serotonin induced activation of ERK1/2 and eNOS.
Human umbilical vein endothelial cells were treated with 1-μM 5-HT for the indicated time. (C) Inhibition of ERK1/2 activity by U0126 and
PD98059. Human umbilical vein endothelial cells were preincubated with 10-μM U0126 or 10-μM PD98059 for 30 minutes, then treated
with 1-μM 5-HT for 5 minutes. (D) Reverse transcription–polymerase chain reaction analysis of selected 5-HT receptors in HUVEC. The
bands representing the 5-HT2A receptor (301 bp), the 5-HT2B receptor (363 bp), the 5-HT2C receptor (354 bp), and GAPDH (268 bp) are
indicated. (E) Western blot analysis to demonstrate the expression of 5-HT2B and 5-HT2C receptors in LLC, KLN205, and HUVEC. The
proteins were detected with polyclonal 5-HT2B receptor and polyclonal 5-HT2C receptor antibodies. Mice forebrain expressed 5-HT2B
and 5-HT2C receptors as a positive control. (F) Inhibition of ERK1/2 activity by SB204741. Human umbilical vein endothelial cells were
preincubated with 10-μM SB204741 or 10-μM RS102221 for 30 minutes, then treated with 1-μM 5-HT for 5 minutes. Phosphorylation of
ERK1/2 and eNOS was determined by Western blot analysis using phosphospecific antibodies.
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The effect of 5-HT depletion may be attributed to the specific vaso-
dilating effect of 5-HT on the vessels supplying oxygen and nutrients
to tumors. This hypothesis is supported by intravital microscopic evi-
dence [6]. Moreover, by investigating eNOS expression in 5-HTT−/−
tumors, we examined the underlying mechanism of why the physio-
logical level of 5-HT is important for the maintenance of blood vessels
supplying the blood flow to tumors. We found that eNOS protein was
reduced in the tumors of 5-HTT−/− mice. Furthermore, we confirmed
the importance of 5-HT in eNOS protein expression and phosphory-
lation in endothelial cells. Under the physiological level of 5-HT,
5-HT induced eNOS protein and phosphorylation of eNOS in a
concentration-dependent manner, suggesting that constitutive eNOS
is regulated in the presence of 5-HT in tumors.
It has been reported that 5-HT stimulates phosphorylation of
ERK1/2 in bovine endothelial cells [26,46], and the 5-HT2B recep-
tor was reported to play a role in the activation of eNOS in human
endothelial cells [21]. Therefore, we focused on the 5-HT receptor 2
family, especially the 5-HT2B receptor. Our results indicate that the
5-HT2B receptor plays a pivotal role in the phosphorylation of both
ERK1/2 and eNOS in HUVEC. The 5-HT2B receptor antagonists
have been found to inhibit colon cancer [19], and our results suggest
that 5-HT2B receptor antagonists reduce tumor growth by inhibiting
angiogenesis through phosphorylation of ERK1/2 and eNOS.
There are no differences in MVD between tumor-bearing 5-HTT+/+
and 5-HTT −/− mice, whereas SB204741 treatment decrease MVD.
Because the level of 5-HT in the tumor of 5-HTT −/− mice was reduced
to half of that in 5-HTT +/+ mice (Figure 1C ), 5-HT2B receptor in
the tumor of 5-HTT −/− mice was stimulated to a certain extent. How-
ever, because SB204741 is specific and strong antagonist of 5-HT2B
receptor, 5-HT2B receptor in the tumor of SB204741-treated mice was
Figure 5. SB204741 reduced tumor growth. (A) Mice were injected s.c. with KLN205 on day 0 and were treated with saline (closed
squares), SB204741 (circles), or RS102221 (open squares) from day 6, every 2 days. (B) Mice were injected s.c. with LLC on day 0
and were treated with saline (closed squares), SB204741 (circles), or RS102221 (open squares) from day 6, every 2 days. Tumor volumes
were calculated from tumor measurement scores on the indicated day. Results are presented as the mean tumor volume ± SD.
(n = 8 per group). *Statistically significant (P < .05) compared with saline-treated mice. (C) When the diameter of the tumors reached
1 cm, mice were killed. Bars, 100 μm. Hematoxylin and eosin–stained sections of KLN205 or LLC tumors (left). Representative sections
of tumors stained for factor VIII as a vascular endothelial marker (right; original magnification, ×200).
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strongly blocked. Our data might suggest that less 5-HT2B receptor stim-
ulation could not decrease MVD, but completely blocking the 5-HT2B
receptor could decrease MVD.
From the standpoint of therapeutic applications, there is an in-
creasing evidence that the 5-HT2B receptor located on endothelial
cells of meningeal blood may be implicated in the pathophysiology
of migraine through the NO pathway [47]. In addition, recent stud-
ies have shown that the 5-HT2B receptor mediates the excitatory
effects of 5-HT in the human colon [48], indicating that antagonists
of this receptor might be valuable for treatment of irritable bowel
syndrome [49]. We found that selective blockade of the 5-HT2B
receptor resulted in the inhibition of tumor angiogenesis and growth
through the inhibition effect of ERK1/2 and eNOS.
Recently, 5-HT–related medicines have been extensively used in
many clinical settings such as psychiatric and coagulation disorders. In
addition to the possibility of the 5-HT2B receptor as a molecular target,
our study suggests that we should be cautious in the use of 5-HT–
related medicines in patients with solid tumors or with a risk of cancer.
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Figure W1. (A) Bars, 100 μm. Hematoxylin and eosin–stained sections of LLC tumors (left). Representative sections of tumors stained
for factor VIII as a vascular endothelial marker (right; original magnification, ×200). (B) Microvessel densities were calculated. Results
are indicated as the mean ± SD of six mice in each group. N.S.: not significant by one-way ANOVA with Fisher’s least significant
difference test.
Figure W2. Human umbilical vein endothelial cells, LLCs, and KLN205 cells (5.0 × 103 cells) were cultured with the indicated amounts of
SB204741 or RS102221. Each cell was cultured for 48 hours. Cell numbers were determined by water-soluble tetrazolium assay. Data
are shown as the mean ± SD of triplicate samples. The values were considered significant (*P < .05) versus controls. Similar results were
obtained from three independent experiments.
